About The Study: This cohort study found that in people with SARS-CoV-2 infection who had at least one risk factor for progression to severe disease, treatment with nirmatrelvir within five days of a positive SARS-CoV-2 test result was associated with reduced risk of post−COVID-19 condition (also known as long COVID) across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection. The totality of the findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post–acute adverse health outcomes.
Authors: Ziyad Al-Aly, M.D., of the VA St. Louis Health Care System in St. Louis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2023.0743)
